8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
May 7, 2026·SEC
Tonix Pharmaceuticals Holding Corp.(TNXP)Earnings, Financials & Key Ratios
TNXP•NASDAQ
$13.22
Price updated Jun 27, 2026
AboutTonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.Show more
- Revenue$13M+29.8%
- EBITDA-$124M+7.1%
- Net Income-$124M+4.6%
- EPS (Diluted)-14.57+91.7%
- Gross Margin34.65%+50.2%
- EBITDA Margin-944.37%+28.5%
- Operating Margin-959.05%+29.2%
- Net Margin-946.22%+26.6%
- ROE-64.48%+39.2%
TNXP Price & Volume
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Overshadows Revenue Growth Acceleration
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Accelerating
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial failure risk
"Tonix Pharmaceuticals exhibits a high-risk profile characterized by aggressive revenue growth, which reached 183.2% year-over-year in 2026Q1, yet remains fundamentally undermined by structural margin volatility and persistent operating losses. While the company maintains a $185.5 million cash position to support its R&D-heavy pipeline, the cumulative deficit of $894.9 million in retained earnings highlights a reliance on dilutive financing. Investors should monitor whether the company can transition from its current high-burn clinical stage to a sustainable commercial model without further eroding shareholder equity."
Verdict Logic
the company's inability to generate positive operating cash flow, evidenced by a -$42.3 million outflow in 2026Q1, suggests that ongoing dilution remains a primary risk for long-term equity holders.
TNXP Growth Metrics
Tonix Pharmaceuticals Holding Corp. (TNXP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM74.84%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-11.72%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.24%
Return on Capital
10 Years-93.37%
5 Years-68.7%
3 Years-76.97%
Last Year-64.31%
Peers Comparison
Key metrics vs top competitors for Tonix Pharmaceuticals Holding Corp. (TNXP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.22 | $210.74M | -0.91 | 29.85% | -946.22% | -64.48% | — | |
| $241.67 | $12.44B | -65.67 | 65.55% | -26.59% | -260.01% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — | |
| $46.84 | $2.7B | -68.88 | 8.63% | -3.74% | -2.73% | — | |
| $87.32 | $9.37B | 106.49 | 12.79% | 6.23% | 7.5% | — | |
| $25.24 | $992.82M | 157.75 | 3.63% | 1.27% | 1.31% | — |
Compare TNXP vs Peers
Tonix Pharmaceuticals Holding Corp. (TNXP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TNXP SEC Filings & Documents
Tonix Pharmaceuticals Holding Corp. (TNXP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TNXP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TNXP Frequently Asked Questions
Tonix Pharmaceuticals Holding Corp. (TNXP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Tonix Pharmaceuticals Holding Corp.'s revenue?
Tonix Pharmaceuticals Holding Corp. (TNXP) reported $17.6M in revenue for fiscal year 2025.
How fast is Tonix Pharmaceuticals Holding Corp. growing?
Tonix Pharmaceuticals Holding Corp. (TNXP) grew revenue by 29.8% over the past year. This is strong growth.
Is TNXP profitable?
Tonix Pharmaceuticals Holding Corp. (TNXP) reported a net loss of $147.4M for fiscal year 2025.
Dividend & Returns
What is TNXP's return on equity?
Tonix Pharmaceuticals Holding Corp. (TNXP) has a return on equity (ROE) of -64.5%. Negative ROE indicates the company is unprofitable.
What is Tonix Pharmaceuticals Holding Corp.'s free cash flow?
Tonix Pharmaceuticals Holding Corp. (TNXP) had negative free cash flow of $132.7M in fiscal year 2025, likely due to heavy capital investments.